You are here: Home Molekulare Medizin und Zellforschung AG Brummer Veröffentlichungen
Document Actions


2022 Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2022 Dec 14:S0168-8278(22)03328-1. doi: 10.1016/j.jhep.2022.11.030. Epub ahead of print. PMID: 36528236.
  Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.
Front Oncol. 2022 Jul 27;12:931774. doi: 10.3389/fonc.2022.931774. eCollection 2022. PMID: 35965494
  Hölzen L, Mitschke J, Schönichen C, Hess ME, Ehrenfeld S, Boerries M, Miething C, Brummer T, Reinheckel R. RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells.
Theranostics. 2022 May 16;12(9):4348-4373. doi: 10.7150/thno.68299. eCollection 2022. PMID: 35673573
  Haimovici A, Höfer C, Badr MT, Haghighi EB, Amer T, Boerries M, Bronsert P, Glavynskyi I, Fanfone D, Ichim G, Thilmany N, Weber A, Brummer T, Spohr C, Öllinger R, Janssen KP, Rad R, Häcker G. Spontaneous activity of the mitochondrial apoptosis pathway drives chromosomal defects, the appearance of micronuclei and cancer metastasis through the Caspase-Activated DNAse.
Cell Death Dis. 2022 Apr 7;13(4):315. doi: 10.1038/s41419-022-04768-y. PMID: 35393399
  Corinna Spohr C, Poggio T, Andrieux G, Schönberger K, Cabezas-Wallscheid N, Boerries M, Halbach S, Illert AL, Brummer T. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
Leukemia. 2022 Apr;36(4):970-982. doi: 10.1038/s41375-021-01490-0. PMID: 34903841
2021 Corrales E, Levit-Zerdoun E, Metzger P, Kowar S, Ku M, Brummer T, Boerries M. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Commun Signal. 2021 Dec 20;19(1):123. doi: 10.1186/s12964-021-00801-3. PMID: 34930313.
  Spohr C, Poggio T, Andrieux G, Schönberger K, Cabezas-Wallscheid N, Boerries M, Halbach S, Illert AL, Brummer T. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. Leukemia. 2021 Dec 13. doi: 10.1038/s41375-021-01490-0. Epub ahead of print. PMID: 34903841.
  Walter C, Marada A, Suhm T, Ernsberger R, Muders V, Kücükköse C, Sánchez-Martín P, Hu Z, Aich A, Loroch S, Solari FA, Poveda-Huertes D, Schwierzok A, Pommerening H, Matic S, Brix J, Sickmann A, Kraft C, Dengjel J, Dennerlein S, Brummer T, Vögtle FN, Meisinger C. Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery. Nat Commun. 2021 Jul 13;12(1):4284. doi: 10.1038/s41467-021-24426-9. PMID: 34257281.
  Osswald L, Hamarsheh S, Uhl FM, Andrieux G, Klein C, Dierks C, Duquesne S, Braun LM, Schmitt-Graeff A, Duyster J, Boerries M, Brummer T, Zeiser R. Oncogenic Kras-G12D activation in the non-hematopoietic bone marrow microenvironment causes myelodysplastic syndrome in mice. Mol Cancer Res. 2021 Jun 4:molcanres.0275.2020. doi: 10.1158/1541-7786.MCR-20-0275. Epub ahead of print. PMID: 34088868.
  Catalano A, Adlesic M, Kaltenbacher T, Klar RFU, Albers J, Seidel P, Brandt LP, Hejhal T, Busenhart P, Röhner N, Zodel K, Fritsch K, Wild PJ, Duyster J, Fritsch R, Brummer T, Frew IJ. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers (Basel). 2021 Apr 13;13(8):1852. doi: 10.3390/cancers13081852. PMID: 33924486; PMCID: PMC8069437.
  Hoefflin R, Lazarou A, Hess ME, Reiser M, Wehrle J, Metzger P, Frey AV, Becker H, Aumann K, Berner K, Boeker M, Buettner N, Dierks C, Duque-Afonso J, Eisenblaetter M, Erbes T, Fritsch R, Ge IX, Geißler AL, Grabbert M, Heeg S, Heiland DH, Hettmer S, Kayser G, Keller A, Kleiber A, Kutilina A, Mehmed L, Meiss F, Poxleitner P, Rawluk J, Ruf J, Schäfer H, Scherer F, Shoumariyeh K, Tzschach A, Peters C, Brummer T, Werner M, Duyster J, Lassmann S, Miething C, Boerries M, Illert AL, von Bubnoff N. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers (Basel). 2021 Mar 8;13(5):1151. doi: 10.3390/cancers13051151. Pubmed33800365.
  Volckmar AL, Christopoulos P, Kirchner M, Allgäuer M, Neumann O, Budczies J, Rempel E, Horak P, Glade J, Goldschmid H, Seker-Cin H, Brandt R, Kriegsmann M, Leichsenring J, Winter H, Faehling M, Fischer JR, Heußel CP, Herth F, Brummer T, Fröhling S, Schirmacher P, Thomas M, Endris V, Penzel R, Kazdal D, Bochtler T, Stenzinger A. Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field. Lung Cancer. 2021 Feb 19;154:131-141. doi: 10.1016/j.lungcan.2021.02.022. Epub ahead of print.Pubmed33667718.
2020 Hamarsheh S, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020 Oct 28;11(1):5439. doi: 10.1038/s41467-020-19288-6. Pubmed33116132
  Uhl FM, Chen S, O'Sullivan D, Edwards-Hicks J, Richter G, Haring E, Andrieux G, Halbach S, Apostolova P, Büscher J, Duquesne S, Melchinger W, Sauer B, Shoumariyeh K, Schmitt-Graeff A, Kreutz M, Lübbert M, Duyster J, Brummer T, Boerries M, Madl T, Blazar BR, Groß O, Pearce EL, Zeiser R. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med. 2020 Oct 28;12(567):eabb8969. doi: 10.1126/scitranslmed.abb8969. Pubmed33115954
  Ketterer S, Mitschke J, Ketscher A, Schlimpert M, Reichardt W, Baeuerle N, Hess ME, Metzger P, Boerries M, Peters C, Kammerer B, Brummer T, Steinberg F, Reinheckel T. Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling. Nat Commun. 2020 Oct 12;11(1):5133. doi: 10.1038/s41467-020-18935-2. Pubmed33046706
  Reischmann N, Andrieux G, Griffin R, Reinheckel T, Boerries M, Brummer T. BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation. Oncogene. 2020 Sep;39(38):6053-6070. doi: 10.1038/s41388-020-01414-9. Pubmed32792685
  Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian BA, Schmitt-Graeff A, Pfeifer D, Catalano A, Frew I, Proietti M, Grimbacher B, Bulashevska A, Bhatt AS, Brummer T, Clauditz TS, Zabelina T, Kroeger N, Blazar BR, Boerries M, Ayuk F, Zeiser R. Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. Blood. 2020 Sep 17;136(12):1442-1455. doi: 10.1182/blood.2020005957. Pubmed32542357
  Kücükköse C, Taskin AA, Marada A, Brummer T, Dennerlein S, Vögtle Functional coupling of presequence processing and degradation in human mitochondria. FN. FEBS J. 2020 Jun 3. doi: 10.1111/febs.15358. Pubmed32491259 Online ahead of print
  Usta D, Sigaud R, Buhl JL, Selt F, Marquardt V, Pauck D, Jansen J, Pusch S, Ecker J, Hielscher T, Vollmer J, Sommerkamp AC, Rubner T, Hargrave D, van Tilburg CM, Pfister SM, Jones DTW, Remke M, Brummer T, Witt O, Milde T. A cell-based MAPK reporter assay reveals synergistic MAPK pathway activity suppression by MAPK inhibitor combination in BRAF-driven pediatric low-grade glioma cells. Mol Cancer Ther. 2020 Aug;19(8):1736-1750. doi: 10.1158/1535-7163.MCT-19-1021. Pubmed32451331
  Brummer T, McInnes C. RAF kinase dimerization: implications for drug discovery and clinical outcomes. Oncogene. 2020 May;39(21):4155-4169. doi: 10.1038/s41388-020-1263-y. Epub 2020 Apr 8. Pubmed32269299 Review
  Hamarsheh S, Osswald L, Saller BS, Unger S, De Feo D, Vinnakota JM, Konantz M, Uhl FM, Becker H, Lübbert M, Shoumariyeh K, Schürch C, Andrieux G, Venhoff N, Schmitt-Graeff A, Duquesne S, Pfeifer D, Cooper MA, Lengerke C, Boerries M, Duyster J, Niemeyer CM, Erlacher M, Blazar BR, Becher B, Groß O, Brummer T, Zeiser R. Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun. 2020 Apr 3;11(1):1659. doi: 10.1038/s41467-020-15497-1. Pubmed32246016
  Weinberg F, Griffin R, Fröhlich M, Heining C, Braun S, Spohr C, Iconomou M, Hollek V, Röring M, Horak P, Kreutzfeldt S, Warsow G, Hutter B, Uhrig S, Neumann O, Reuss D, Heiland DH, von Kalle C, Weichert W, Stenzinger A, Brors B, Glimm H, Fröhling S, Brummer T. Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene. 39 (4), 814-832 Jan 2020. doi: 10.1038/s41388-019-1021-1. Pubmed31558800
2019 Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, de Oliveira CMM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Int J Cancer.2019 Aug 1;145(3):649-661. doi: 10.1002/ijc.32133. Epub 2019 Feb 19. Pubmed30653256
  Beneker CM, Rovoli M, Kontopidis G, Röring M, Galda S, Braun S, Brummer T, McInnes C. Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. J Med Chem.2019 Apr 25;62(8):3886-3897. doi: 10.1021/acs.jmedchem.8b01288. Epub 2019 Apr 12. Pubmed30977659
  Sies K, Spohr C, Gründer A, Todorova R, Uhl FM, Huber J, Zeiser R, Pahl HL, Becker H, Aumann K, Brummer T, Halbach S. Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia. Hemasphere. 2019 Feb 22;3(2):e184. doi: 10.1097/HS9.0000000000000184. eCollection 2019 Apr. Pubmed31723823
  Köhler M, Ehrenfeld S, Halbach S, Lauinger M, Burk U, Reischmann N, Cheng S, Spohr C, Uhl FM, Köhler N, Ringwald K, Braun S, Peters C, Zeiser R, Reinheckel T, Brummer T. B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. Oncogene. 2019 Feb;38(8):1324-1339. doi: 10.1038/s41388-018-0663-8. Epub 2019 Jan 18. Pubmed30659267
  Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, Ridinger J, Riehl D, Usta D, Ismer B, Sommerkamp AC, Martinez-Babera JP, Wefers AK, Remke M, Picard D, Pusch S, Gronych J, Oehme I, van Tilburg CM, Kool M, Kuhn D, Capper D, von Deimling A, Schuhmann M, Herold-Mende C, Korshunov A, Brummer T, Pfister SM, Jones DTW, Witt O, Milde T. The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma. Clin Cancer Res. 2019 Mar 15;25(6):1851-1866. doi: 10.1158/1078-0432.CCR-18-1965. Epub 2018 Dec 7. Pubmed30530705
2018 Hoefflin, R.,Geißler, A.-L., Fritsch, R., Claus, R.,,Wehrle, J., Metzger, P., Reiser, M., Mehmed, L., Fauth, L., Heiland, D.H., Erbes, T., Stock, F.,,Csanadi, A., Miething, C., Weddeling, B., Meiss, F., von Bubnoff, D., Dierks, C., Ge, I., Brass, V., Heeg, S., Schäfer, H., Boeker, M., Rawluk, J., Botzenhart, E.M., Kayser, G., Hettmer, S., Busch, H., Peters, C., Werner, M., Duyster, J., Brummer, T., Boerries, M., Lassmann, S. and von Bubnoff, N. (2018). Personalized clinical decision making through implementation of a Molecular Tumorboard – a German single centre experience. JCO Precision Oncology, DOI: 10.1200/PO.18.00105 JCO Precision Oncology - published online August 16, 2018
  Schorch B, Heni H, Zahaf NI, Brummer T, Mione M, Schmidt G, Papatheodorou P, Aktories K. Targeting oncogenic Ras by the Clostridium perfringens toxin TpeL. Oncotarget. 2018 Mar 27;9(23):16489-16500. doi: 10.18632/oncotarget.24740. eCollection 2018 Mar 27. Pubmed29662661
  Herr R, Halbach S, Heizmann M, Busch H, Boerries M, Brummer T. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene. 2018 Mar;37(12):1576-1593. doi: 10.1038/s41388-017-0063-5. Pubmed29326440
  Mathew NR, Baumgartner F, Braun L, ......... Halbach S, Brummer T, ........ Andrieux G, Börries M, ....... Blazar BR, Zeiser R. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Pubmed29634689
  Prestipino A,...... Boerries M, Busch H, Halbach S, ......Brummer T, ... Zeiser R. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729. Pubmed29467301
  Brauns-Schubert P, Schubert F, Wissler M, Weiss M, Schlicher L, Bessler S, Safavi M, Miething C, Borner C, Brummer T, Maurer U. CDK9-mediated phosphorylation controls the interaction of TIP60 with the transcriptional machinery. EMBO Rep. 2018 Feb;19(2):244-256. doi: 10.15252/embr.201744311. Epub 2018 Jan 15. Pubmed29335245
2017 Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation. Leukemia. 2017 Dec;31(12):2732-2741. doi: 10.1038/leu.2017.137. Epub 2017 May 9. Pubmed28484267
  Lang S, Busch H, Boerries M, Brummer T, Timme S, Lassmann S, Aktories K, Schmidt G. Specific role of RhoC in tumor invasion and metastasis. Oncotarget. 2017 Sep 16;8(50):87364-87378. doi: 10.18632/oncotarget.20957. eCollection 2017 Oct 20. Pubmed29152087
  Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Mittapalli VR, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R. Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget. 2017 Jun 27;8(26):42901-42916. doi: 10.18632/oncotarget.17160. Pubmed28476030
  Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Köhler M, Halbach S, Becker AC, Deng N, Schmitz T, Uhl FM, Herbener N, Riedel B, Beier F, Swarbrick A, Lassmann S, Dengjel J, Zeiser R, Brummer T. The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior. EBioMedicine. 2017 Jun;20:79-97. doi: 10.1016/j.ebiom.2017.04.015. Epub 2017 Apr 12. Pubmed28499923
  Diedrich B, Rigbolt KT, Röring M, Herr R, Kaeser-Pebernard S, Gretzmeier C, Murphy RF, Brummer T, Dengjel J. Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. EMBO J. 2017 Mar 1;36(5):646-663. doi: 10.15252/embj.201694732. Pubmed 28093501
  Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Marquardt V, Pauck D, Bächli H, Stiles CD, von Deimling A, Remke M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, Milde T. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget. 2017 Feb 14;8(7):11460-11479. doi: 10.18632/oncotarget.14004 Pubmed 28002790
2016 Maier K, He Y, Wölfle U, Esser PR, Brummer T, Schempp C, Bruckner-Tuderman L, Has C. UV-B-induced cutaneous inflammation and prospects for antioxidant treatment in Kindler syndrome. Hum Mol Genet. 2016 Dec 15;25(24):5339-5352. doi: 10.1093/hmg/ddw350. Pubmed 27798104
  Young AI, Law AM, Castillo L, Chong S, Cullen HD, Koehler M, Herzog S, Brummer T, Lee EF, Fairlie WD, Lucas MC, Herrmann D, Allam A, Timpson P, Watkins DN, Millar EK, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Res. 2016 Dec 8;18(1):125. Pubmed 27931239
  International Cancer Genome Consortium PedBrain Tumor Project.. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 2016 Nov;22(11):1314-1320. doi: 10.1038/nm.4204. Pubmed 27748748
  Halbach S, Dengjel J, Brummer T. Quantitative Proteomics Analysis of Leukemia Cells. Methods Mol Biol. 2016;1465:139-48. doi: 10.1007/978-1-4939-4011-0_12. Pubmed 27581145
  Halbach S, Köhler M, Uhl FM, Huber J, Zeiser R, Koschmieder S, Aumann K, Brummer T. Gab2 is essential for Bcr-Abl mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. Leukemia. 2016 Sep;30(9):1942-5. doi: 10.1038/leu.2016.92. Epub 2016 Apr 29. Pubmed 27125306
  Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T. BRAF inhibition in hairy cell leukemia with low dose vemurafenib. Blood. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Pubmed 26941398
  Eisenhardt AE, Sprenger A, Röring M, Herr R, Weinberg F, Köhler M, Braun S, Orth J, Diedrich B, Lanner U, Tscherwinski N, Schuster S, Dumaz N, Schmidt E, Baumeister R, Schlosser A, Dengjel J, Brummer T. Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.Oncotarget. 2016 May 3;7(18):26628-52. doi: 10.18632/oncotarget.8427. Pubmed 27034005
  Köhler M, Brummer T. B-Raf activation loop phosphorylation revisited. Cell Cycle. 2016 May 2;15(9):1171-3. doi: 10.1080/15384101.2016.1159111. Epub 2016 Apr 21. Pubmed 27100935
  Bier D, Bartel M, Sies K, Halbach S, Higuchi Y, Haranosono Y, Brummer T, Kato N, Ottmann C. Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface. ChemMedChem. 2016 Apr 19;11(8):911-8. doi: 10.1002/cmdc.201500484. Epub 2015 Dec 8. Pubmed 26644359
  Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia. 2016 Apr;30(4):937-46. doi: 10.1038/leu.2015.319. Epub 2015 Nov 19. Pubmed26582644
  Halbach S, Hu Z, Gretzmeier C, Ellermann J, Wöhrle FU, Dengjel J, Brummer T. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Cell Commun Signal. 2016 Feb 24;14(1):6. doi: 10.1186/s12964-016-0129-y. Pubmed 26912052
  Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP, Brabletz T. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun. 2016 Feb 15;7:10498. doi: 10.1038/ncomms10498. Pubmed 26876920
  Fritsche-Guenther R, Witzel F, Kempa S, Brummer T, Sers C, Blüthgen N.Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. Oncotarget. 2016 Feb 16;7(7):7960-9. doi: 10.18632/oncotarget.6959. Pubmed 26799289
  Köhler M, Röring M, Schorch B, Heilmann K, Stickel N, Fiala GJ, Schmitt LC, Braun S, Ehrenfeld S, Uhl FM, Kaltenbacher T, Weinberg F, Herzog S, Zeiser R, Schamel WW, Jumaa H, Brummer T. Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants. EMBO J. 2016 Jan 18;35(2):143-61. doi: 10.15252/embj.201592097. Epub 2015 Dec 10. Pubmed 26657898
2015 Herr R, Brummer T. BRAF inhibitors in colorectal cancer: Toward a differentiation therapy? Mol Cell Oncol. 2015 Jan 23;2(4):e1002709. doi: 10.1080/23723556.2014.1002709. eCollection 2015 Oct-Dec. Pubmed 27308494
  Boerries M, Herr R, Brummer T, Busch H. Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines. Genom Data. 2015 Apr 28;4:158-61. doi: 10.1016/j.gdata.2015.04.015. eCollection 2015 Jun. Pubmed26484206
  Fiala GJ, Janowska I, Prutek F, Hobeika E, Satapathy A, Sprenger A, Plum T, Seidl M, Dengjel J, Reth M, Cesca F, Brummer T, Minguet S, Schamel WW. Kidins220/ARMS binds to the B cell antigen receptor and regulates B cell development and activation. J Exp Med. 2015 Sep 21;212(10):1693-708. doi: 10.1084/jem.20141271. Epub 2015 Aug 31. Pubmed26324445
  Preca BT, Bajdak K, Mock K, Sundararajan V, Pfannstiel J, Maurer J, Wellner U, Hopt UT, Brummer T, Brabletz S, Brabletz T, Stemmler MP. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int J Cancer. 2015 Dec 1;137(11):2566-77. doi: 10.1002/ijc.29642. Epub 2015 Jun 30. Pubmed26077342
  Fischer A, Brummer T, Warscheid B, Radziwill G. Differential tyrosine phosphorylation controls the function of CNK1 as a molecular switch in signal transduction. Biochim Biophys Acta. 2015 Nov;1853(11 Pt A):2847-2855. doi: 10.1016/j.bbamcr.2015.08.014. Epub 2015 Aug 28.. Pubmed26319181
  Willmann L, Erbes T, Halbach S, Brummer T, Jäger M, Hirschfeld M, Fehm T, Neubauer H, Stickeler E, Kammerer B. Exometabolom analysis of breast cancer cell lines: Metabolic signature. Sci Rep. 2015 Aug 21;5:13374. doi: 10.1038/srep13374. Pubmed26293811
  Willmann L, Schlimpert M, Halbach S, Erbes T, Stickeler E, Kammerer B. Metabolic profiling of breast cancer: Differences in central metabolism between subtypes of breast cancer cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 1;1000:95-104. doi: 10.1016/j.jchromb.2015.07.021. Epub 2015 Jul 14. Pubmed26218769
  Mock K, Preca BT, Brummer T, Brabletz S, Stemmler MP, Brabletz T. The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors. Oncotarget.2015 Jun 10;6(16):14399-412. Pubmed25973542
  Herr R, Köhler M, Andrlova H, Weinberg F, Möller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M, Brummer T. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res. 2015 Jan 1;75(1):216-29. doi: 10.1158/0008-5472.CAN-13-3686. Epub 2014 Nov 7. PMID: 25381152
  Haug S, Schnerch D, Halbach S, Mastroianni J, Dumit VI, Follo M, Hasenburg A, Köhler M, Dierbach H, Herzog S, Proske A, Werner M, Dengjel J, Brummer T, Laßmann S, Wäsch R, Zeiser R. Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer. Int J Cancer. 2015 May 15;136(10):2328-40. doi: 10.1002/ijc.29289. Epub 2014 Nov 8. PMID: 25346496
2014 Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014 Nov 3;124(11):5074-5084. doi: 10.1172/JCI76539.. PMID: 25329694
  Möller Y, Siegemund M, Beyes S, Herr R, Lecis D, Delia D, Kontermann R, Brummer T, Pfizenmaier K, Olayioye MA. EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells. PLoS One. 2014 Sep 8;9(9):e107165. doi: 10.1371/journal.pone.0107165. eCollection 2014. PMID: 25198428
  Sprissler C, Belenki D, Maurer H, Aumann K, Pfeifer D, Klein C, Müller TA, Kissel S, Hülsdünker J, Alexandrovski J, Brummer T, Jumaa H, Duyster J, Dierks C. Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J. 2014 Aug 22;4:e240. doi: 10.1038/bcj.2014.53. PMID: 25148222
  Weinberg F, Schulze E, Fatouros C, Schmidt E, Baumeister R, Brummer T. Expression pattern and first functional characterization of riok-1 in Caenorhabditis elegans. Gene Expr Patterns. 2014 Jul;15(2):124-34. doi: 10.1016/j.gep.2014.05.005. Epub 2014 Jun 12. PMID: 24929033
2013 Yaktapour N, Ubelhart R, Schüler J, Aumann K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, Zirlik K. Insulin-like growth factor 1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood. 2013 Aug 29;122(9):1621-33. doi: 10.1182/blood-2013-02-484386. Epub 2013 Jul 17. PMID: 23863897
  Karlsson M, Lienemann PS, Sprossmann N, Heilmann K, Brummer T, Lutolf MP, Ehrbar M, Weber W. A generic strategy for pharmacological caging of growth factors for tissue engineering. Chem Commun (Camb). 2013 Jul 7;49(53):5927-9. doi: 10.1039/c3cc41616j. PMID: 23715175
  Ortiz-Padilla C, Gallego-Ortega D, Browne BC, Hochgräfe F, Caldon CE, Lyons RJ, Croucher DR, Rickwood D, Ormandy CJ, Brummer T, Daly RJ. Functional characterization of cancer-associated Gab1 mutations. Oncogene. 2013 May 23;32(21):2696-702. doi: 10.1038/onc.2012.271. Epub 2012 Jul 2. Pubmed22751113
  Halbach S, Rigbolt KT, Wöhrle FU, Diedrich B, Gretzmeier C, Brummer T, Dengjel J. Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells. Cell Commun Signal. 2013 Apr 22;11(1):30. doi: 10.1186/1478-811X-11-30. Pubmed23607741
  Deswal S, Meyer A, Fiala GJ, Eisenhardt AE, Schmitt LC, Salek M, Brummer T, Acuto O, Schamel WW. Kidins220/ARMS Associates with B-Raf and the TCR, Promoting Sustained Erk Signaling in T Cells.J Immunol. 2013 Mar 1;190(5):1927-35. doi: 10.4049/jimmunol.1200653. Epub 2013 Jan 28. Pubmed23359496
  Kienzle C, Eisler SA, Villeneuve J, Brummer T, Olayioye MA, Hausser A. PKD controls mitotic Golgi complex fragmentation through a Raf-MEK1 pathway. Mol Biol Cell. 2013 Feb;24(3):222-33. doi: 10.1091/mbc.E12-03-0198. Epub 2012 Dec 14. Pubmed23242995
  Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia. 2013 Jan;27(1):118-29. doi: 10.1038/leu.2012.222. Epub 2012 Aug 3. Pubmed22858987
2012 Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ. ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. PLoS Biol. 2012 Dec;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27. Pubmed23300383
  Wöhrle FU, Halbach S, Brummer T. The versatile role of gab1 in the circulatory system. Circ J. 2012;76(8):1838-9. Epub 2012 Jul 11. Pubmed22785000
  Ortiz-Padilla C, Gallego-Ortega D, Browne BC, Hochgräfe F, Caldon CE, Lyons RJ, Croucher DR, Rickwood D, Ormandy CJ, Brummer T, Daly RJ. Functional characterization of cancer-associated Gab1 mutations. Oncogene. 2012 Jul 2. doi: 10.1038/onc.2012.271. Pubmed22751113 [Epub ahead of print]

Holeiter G, Bischoff A, Braun AC, Huck B, Erlmann P, Schmid S, Herr R, Brummer T and Olayioye MA. The RhoGAP protein Deleted in Liver Cancer 3 (DLC3) is essential for adherens junctions integrity. Oncogenesis 1: e13; doi:10.1038/oncsis.2012.13

  Röring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S, Capper D, von Deimling A, Schamel WW, Saunders DN, Brummer T. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 2012 Apr 17;31(11):2629-47. doi: 10.1038/emboj.2012.100. Pubmed22510884
  Röring M, Brummer T. Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside. Crit Rev Oncog. 2012;17(1):97-121. Review. Pubmed22471666
  Sigglekow ND, Pangon L, Brummer T, Molloy M, Hawkins NJ, Ward RL, Musgrove EA, Kohonen-Corish MR. Mutated in colorectal cancer protein modulates the NFκB pathway. Anticancer Res. 2012 Jan;32(1):73-9. Pubmed22213290

Herr R, Wöhrle FU, Danke C, Berens C, Brummer T. A novel MCF-10A line allowing conditional oncogene expression in 3D culture. Cell Commun Signal. 2011 Jul 13;9:17. Pubmed21752278

  Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Blüthgen N. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol. 2011 May 24;7:489. Pubmed21613978
  Aumann K, Lassmann S, Schöpflin A, May AM, Wöhrle FU, Zeiser R, Waller CF, Hauschke D, Werner M, Brummer T. The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. Hum Pathol. 2011 May;42(5):719-26. Epub 2011 Feb 2. Pubmed21292300
  Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, Kulozik AE, Gnekow A, Scheurlen W, Witt O, Omran H, Jabado N, Collins VP, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister SM. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011 Jun;121(6):763-74. Epub 2011 Mar 20. Pubmed21424530
  Eisenhardt AE, Olbrich H, Röring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer. 2011 Nov 1;129(9):2297-303. doi: 10.1002/ijc.25893. Epub 2011 Jul 25. Pubmed21190184
  Herrera Abreu MT, Hughes WE, Mele K, Lyons RJ, Rickwood D, Browne BC, Bennett HL, Vallotton P, Brummer T, Daly RJ. Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. Mol Biol Cell. 2011 Jan 1;22(1):105-16. Epub 2010 Nov 30. Pubmed21118992
2010 Brummer T, Schmitz-Peiffer C, Daly RJ. Docking proteins. FEBS J. 2010 Nov;277(21):4356-69. doi: 10.1111/j.1742-4658.2010.07865.x. Epub 2010 Sep 30. Review. Pubmed20883498
  Patterson KI, Brummer T, Daly RJ, O'Brien PM. DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs. Biochim Biophys Acta. 2010 Sep;1803(9):1003-12. Epub 2010 Mar 27. Pubmed20347885
  Fleuren ED, O'Toole S, Millar EK, McNeil C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D, Brummer T, Penninger JM, Sutherland RL, Daly RJ. Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. Int J Cancer. 2010 Sep 1;127(6):1486-92. Pubmed20087860
  Brummer T. GAB2 (GRB2-associated binding protein 2). Atlas Genet Cytogenet Oncol Haematol. January 2010. http://documents.irevues.inist.fr/bitstream/2042/44870/1/01-2010-GAB2ID40664ch11q14.pdf
2009 Wöhrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal. 2009 Sep 8;7:22. Pubmed19737390
  Wöhrle FU, Daly RJ, Brummer T. How to Grb2 a Gab. Structure. 2009 Jun 10;17(6):779-81. Pubmed19523893
  Patterson KI, Brummer T, O'Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009 Mar 15;418(3):475-89. Review. Pubmed19228121
2008 Brummer T, Larance M, Herrera Abreu MT, Lyons RJ, Timpson P, Emmerich CH, Fleuren ED, Lehrbach GM, Schramek D, Guilhaus M, James DE, Daly RJ. Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J. 2008 Sep 3;27(17):2305-16. Pubmed19172738
  Brummer, T. (2008a). “B-Raf signalling” and “B-Raf somatic alterations”. Encyclopedia of Cancer, edited by M. Schwab. (Heidelberg, Springer), pp. 406-413.
  Bennett, H. L., Brummer, T., Timpson, P., Patterson, K. I., and Daly, R. J. (2008b). Signaling by the EGF Receptor in Human Cancers: Accentuate the Positive, Eliminate the Negative. In EGFR Signaling Networks in Cancer Therapy, J. D. Haley, and W. J. Gullick, eds. (Totoja, N.J., USA, Humana Press), pp. 235-255
  Bennett HL, Brummer T, Jeanes A, Yap AS, Daly RJ. Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis. Oncogene. 2008 Apr 24;27(19):2693-704. Epub 2007 Nov 12. Pubmed17998934
2006 Brummer T, Martin P, Herzog S, Misawa Y, Daly RJ, Reth M. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene. 2006 Oct 12;25(47):6262-76. Epub 2006 May 15. Pubmed16702958
  Jeffrey, K.L., Mackay, C.R. and Brummer, T. (2006): Transfection of bone marrow-derived mast cells for transcription factor luciferase reporter assays. Nature Protocols, Protocols network online publication DOI:10.1038/nprot.2006.218. http://www.natureprotocols.com/2006/09/12/transfection_of_bone_marrowder_1.php
  Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, Gillieron C, Mackay F, Grey S, Camps M, Rommel C, Gerondakis SD, Mackay CR. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol. 2006 Mar;7(3):274-83. Epub 2006 Feb 12. Pubmed16474395
  Brummer T, Schramek D, Hayes VM, Bennett HL, Caldon CE, Musgrove EA, Daly RJ. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem. 2006 Jan 6;281(1):626-37. Epub 2005 Oct 27. Pubmed16253990
2005 Minguet S, Huber M, Rosenkranz L, Schamel WW, Reth M, Brummer T. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol. 2005 Jan;35(1):31-41. Pubmed15580656
2004 Brummer T, Elis W, Reth M, Huber M. B-cell signal transduction: tyrosine phosphorylation, kinase activity, and calcium mobilization. Methods Mol Biol. 2004;271:189-212. Pubmed15146122
  Reth M, Brummer T. Feedback regulation of lymphocyte signalling. Nat Rev Immunol. 2004 Apr;4(4):269-77. Review. No abstract available. Pubmed15057785
  Brummer T, Stéhelin D, Misawa Y, Reth M. A revised and complete map of the chicken c-mil/raf-1 locus. Oncogene. 2004 Apr 15;23(17):3128-31. Pubmed14968114
2003 Brummer T, Naegele H, Reth M, Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene. 2003 Dec 4;22(55):8823-34. Pubmed14654779
  Flemming A, Brummer T, Reth M, Jumaa H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol. 2003 Jan;4(1):38-43. Epub 2002 Nov 18. Pubmed12436112
2002 Brummer T, Shaw PE, Reth M, Misawa Y. Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling. EMBO J. 2002 Nov 1;21(21):5611-22. Pubmed12411479


« January 2023 »
Personal tools